Video
Dr. Ascierto on the COLUMBUS Trial in Melanoma
Author(s):
Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses the COLUMBUS trial in melanoma.
Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses the COLUMBUS trial in melanoma.
COLUMBUS was a phase III trial of encorafenib plus binimetinib versus vemurafenib (Zelboraf) or encorafenib in patients with BRAF-mutant melanoma. Median overall survival was 33.6 months (95% CI, 24.4-39.2) with encorafenib plus binimetinib, 23.5 months (95% CI, 19.6-33.6) with encorafenib, and 16.9 months (95% CI, 14.0-24.5) with vemurafenib.
The trial compared a new combination of BRAF and MEK inhibitors with vemurafenib monotherapy, says Ascierto. Encorafenib was shown to be superior to vemurafenib, giving physicians a new and more potent class of BRAF inhibitors.
Physicians now know that adding binimetinib to encorafenib improves survival in patients with BRAF-mutant advanced, unresectable or metastatic melanoma. In terms of the safety profile, encorafenib was associated with less fever and photosensitivity. This will allow patients to stay on treatment longer, says Ascierto.
